BeyondSpring (NASDAQ:BYSI) Stock Price Up 1.3% – Should You Buy?

Posted by Jeff Wilder on Jul 30th, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s share price shot up 1.3% on Tuesday . The stock traded as high as $1.1850 and last traded at $1.1850. Approximately 6,587 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 29,945 shares. The stock had previously closed at $1.17.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Read Our Latest Stock Report on BeyondSpring

BeyondSpring Stock Performance

The company’s 50-day moving average is $1.55 and its 200 day moving average is $1.55. The company has a market capitalization of $46.47 million, a PE ratio of -8.07 and a beta of 0.43.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring at the end of the most recent quarter. 40.29% of the stock is owned by institutional investors and hedge funds.

BeyondSpring Company Profile

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.